UNSPSC 51422113: Diflucortolone pivalate

This classification denotes a therapeutic glucocorticoid C27H36F2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZR05N78276, chemically known as pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-, but more generally known as diflucortolone pivalate, which bears US NIH Compound Identifier 66381. Most nations, for tariff and trade purposes, schedule diflucortolone pivalate under HS 29372200 and SITC 54153.

As of Q4 2014, DIFLUCORTOLONE PIVALATE remains US FDA's Preferred Term for this commodity. Diflucortolone pivalate bears US NLM identifiers UMLS ID C0770953 and NCI Concept Code C65383. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)COC(=O)C(C)(C)C)C)O)F)C)F.

UNSPSC 51422113 Diflucortolone pivalate is a Commodity code for a specific corticosteroid pharmaceutical product, but recent state and local procurement activity under this code shows a significant mismatch with its nominal scope. The Seminole County, Florida IFB for naloxone and drug deactivation systems, and the Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs, address pharmaceutical procurement broadly rather than diflucortolone pivalate specifically. State and local buyers do source pharmaceutical products through coded procurement vehicles, but the recent opportunities visible under this code do not reflect demand for this particular active pharmaceutical ingredient.

The geographic spread of recent activity touches Florida and Texas, though neither solicitation targets diflucortolone pivalate procurement directly. Seminole County's IFB (solicitation number IFB60459723LAS, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) explores vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The code shows little relevant recent activity aligned with its specific pharmaceutical designation, suggesting that either diflucortolone pivalate commands limited procurement volume among state and local health jurisdictions or that solicitations for this product are tagged to broader pharmaceutical family or class codes rather than this commodity level. Firms sourcing specific pharmaceutical actives should verify tagging accuracy in state procurement databases before investing in pursuit.